Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 25, 2013Journal of Crohn s and ColitisOpen Access

ECCO position statement: The use of biosimilar medicines in the treatment of inflammatory bowel disease (IBD)

View Full Paper
Ask AI
Bookmark
Share

Authors

Silvio Danese
Silvio DaneseUniversità Cattolica del Sacro CuoreFGFernando GomollónUniversidad de Zaragoza

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Danese et al. (2013) studied this question.

synapsesocial.com/papers/6a8308a85db41a8ba7af84f3https://doi.org/10.1016/j.crohns.2013.03.011
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Worldwide experience with biosimilar development2011 · 200 citations
  2. 2Biosimilar epoetins and other “follow‐on” biologics: Update on the European experiences2010 · 92 citations
  3. 3Shared Decision Making to Improve Care and Reduce Costs2013 · 765 citations
  4. 4Biosimilars 2.02011 · 15 citations
  5. 5Next generation and biosimilar monoclonal antibodies: Essential considerations towards regulatory acceptance in Europe; February 3-4, 2011; Freiburg, Germany2011 · 28 citations